HOME >> BIOLOGY >> NEWS
24-Wk data from CONTEXT trial comparing GW433908/ritonavir QD & BID to Lopinavir/ritonavir BID

International Congress on Drug Therapy in HIV Infection in Glasgow, United Kingdom.

Efficacy Results From CONTEXT

A total of 320 (315 treated) PI-experienced HIV+ patients experiencing virologic failure (plasma HIV-1 RNA viral load of ?1,000 copies/mL) were enrolled in the CONTEXT study. Forty percent of study participants had prior treatment experience with two or more PIs, 74 percent had experience with 3 or more nucleoside reverse transcriptase inhibitors (NRTIs), and 57 percent had received prior therapy with non-nucleoside reverse transcriptase inhibitors (NNRTIs).

Patients were randomized to receive either 1400 mg of 908 QD combined with low dose ritonavir (200 mg QD) (n=105), 700 mg of 908 combined with 100 mg ritonavir BID (n=107), or 400 mg lopinavir/100 mg ritonavir BID (n=103). All three groups took the medications in combination with two active NRTIs. Baseline vRNA (median 4.14 log10 copies/mL) and CD4+ cell counts (median 263 cells/mm3 ) were similar among the treatment arms.

By intent-to-treat analysis at 24 weeks, the mean AAUCMB (log10 c/mL) was -1.48 for patients on 908/r QD, -1.50 for those on 908/r BID and -1.66 for those taking LPV/r BID, according to DeJesus. Positive antiviral responses were seen with both the 908/r and LPV/r regimens, with 48 percent, 42 percent and 40 percent achieving <50 c/mL responses in the LPV/r, 908/r QD and 908/r BID arms, respectively. The median change from baseline in CD4 cells/mm3 was 72 for 908/r QD, 62 for 908/r BID and 63 for LPV/r BID.

Safety Results from CONTEXT

In the CONTEXT trial, the incidence of drug-related adverse events (AEs) of at least moderate severity was low, occurring in 19 percent of patients on 908/r QD (n=20), 35 percent on 908/r BID (n=37) and 34 percent on LPV/r BID (n=35). The most common AEs were diarrhea (5 percent, 10 percent and 8 percent, respectively) and nausea (4 percent, 3 percent and 9 percent, respectively). Additionally, mo
'"/>

Contact: Amy Kling
akling@pcipr.com
312-558-1770
Public Communications Inc.
14-Feb-2003


Page: 1 2 3 4

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. Innovative ceramic-on-metal hip replacements to undergo clinical trials
3. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
4. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
5. Pharmacogenomics could replace trial-and-error with science from the human genome
6. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
7. Small trial shows daclizumab add-on therapy improves MS outcome
8. Tigecycline - antibiotic evaluated in surveillance trial
9. OneWorld Health completes enrollment, treatment in Phase III India trial
10. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
11. First large-scale trial of genetically personalised treatment for breast cancer to start soon

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... , Dec. 8, 2016 Market Research Future published a ... The global Mobile Biometric Security and Service Market is expected to ... 2022. Market Highlights: ... , Mobile Biometric Security ... to the increasing need of authentication and security from unwanted cyber ...
(Date:12/8/2016)... , Dec. 8, 2016  Singulex, Inc., the leader ... technology, entered into a license and supply agreement with ... The agreement provides Singulex access to Thermo Scientific BRAHMS ... is used to diagnose systemic bacterial infection ... to aid in assessing the risk of ...
(Date:12/7/2016)... India , December 7, 2016 According to a ... Machine Learning), Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, ... is estimated to grow from USD 6.72 Billion in 2016 to USD 36.07 ... Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... -- The Board of Directors of the Pittsburgh Life ... only pure life sciences investment firm, today announced ... plan developed by the Nominating and Governance Committee over ... F. Jordan is selected to serve as President ... , who is elected to the position of Executive ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 This report ... following Product Segments: Acid Based (Humic, Amino, & Fulvic), Extract ... by the following Crop Types: Ornamental & Turf, Row Crops, ... US, Canada , Japan ... , Latin America , and Rest of ...
(Date:12/8/2016)... ... December 08, 2016 , ... Lajollacooks4u, San Diego’s premier team building events ... building events, new program offerings and company expansion. , This is largely ... include groups of over 30 people. Ever since, Lajollacooks4u has seen significant demand for ...
(Date:12/8/2016)... SAN DIEGO, Dec. 8, 2016  OncoSec Medical ... company developing DNA-based intratumoral cancer immunotherapies, today announced ... "We are delivering on our ... melanoma with ImmunoPulse® IL-12. We are pleased with ... melanoma combination trial, and we are focused on ...
Breaking Biology Technology:
Cached News: